CRISPR-Cas9: Catalyst for Oncology Clinical Trials?

crispr-cas9Harnessing Gene-Editing Technology for Oncology Trials

The gene-editing technology has captured the attention of the life science and investment communities not only as an elegant tool in the classical science sense — simple and precise — but also as efficient and easy to use, relative to its predecessors. The ethics and policies surrounding the capability of CRISPR-Cas9 to edit the DNA of any cell are also of interest. CRISPR-Cas9 readily promises to enable or improve the ability to decipher the underlying genetic control, diagnosis and interventions of many diseases, including cancers. And, while no clinical trial of a CRISPR-Cas9-enabled cancer therapeutic has begun, discovery and development programs are underway.

This paper explores the possible applications of CRISPR-Cas9 technology within the oncology clinical trial arena.

Submit this form for download.

By submitting this form you agree to our Terms of Use and Privacy Policy. Information provided by you may be collected and automatically stored in our database and may be used for sending you additional information about Novella and our services. Such information also may be transferred to Novella companies in other countries.
Copyright © 2019 Novella Clinical and its affiliates. All rights reserved.